160 related articles for article (PubMed ID: 11390600)
1. Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter.
Tindle RW; Herd K; Doan T; Bryson G; Leggatt GR; Lambert P; Frazer IH; Street M
J Virol; 2001 Jul; 75(13):5985-97. PubMed ID: 11390600
[TBL] [Abstract][Full Text] [Related]
2. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
3. Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells.
Narayan S; Choyce A; Linedale R; Saunders NA; Dahler A; Chan E; Fernando GJ; Frazer IH; Leggatt GR
Eur J Immunol; 2009 Feb; 39(2):481-90. PubMed ID: 19180468
[TBL] [Abstract][Full Text] [Related]
4. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization.
Doan T; Herd KA; Lambert PF; Fernando GJ; Street MD; Tindle RW
Cancer Res; 2000 Jun; 60(11):2810-5. PubMed ID: 10850419
[TBL] [Abstract][Full Text] [Related]
5. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes.
Doan T; Chambers M; Street M; Fernando GJ; Herd K; Lambert P; Tindle R
Virology; 1998 May; 244(2):352-64. PubMed ID: 9601506
[TBL] [Abstract][Full Text] [Related]
6. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
8. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
9. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects.
Wang-Johanning F; Gillespie GY; Grim J; Rancourt C; Alvarez RD; Siegal GP; Curiel DT
Cancer Res; 1998 May; 58(9):1893-900. PubMed ID: 9581830
[TBL] [Abstract][Full Text] [Related]
10. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
12. Human keratin 14 driven HPV 16 E6/E7 transgenic mice exhibit hyperkeratinosis.
Kim SH; Kim KS; Lee EJ; Kim MO; Park JH; Cho KI; Imakawa K; Hyun BH; Chang KT; Lee HT; Ryoo ZY
Life Sci; 2004 Nov; 75(25):3035-42. PubMed ID: 15474555
[TBL] [Abstract][Full Text] [Related]
13. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
[TBL] [Abstract][Full Text] [Related]
14. Selective absence of CD8+ TCRalpha beta+ intestinal epithelial cells in transgenic mice expressing beta2-microglobulin-associated ligands exclusively on thymic cortical epithelium.
Capone M; Lees RK; Finke D; Ernst B; Meerwijk JP; MacDonald HR
Eur J Immunol; 2003 Jun; 33(6):1471-7. PubMed ID: 12778464
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
Herd KA; Harvey T; Khromykh AA; Tindle RW
Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
[TBL] [Abstract][Full Text] [Related]
16. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
Herd K; Fernando GJ; Dunn LA; Frazer IH; Lambert P; Tindle RW
Virology; 1997 Apr; 231(1):155-65. PubMed ID: 9143315
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
18. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
19. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
20. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
Préville X; Ladant D; Timmerman B; Leclerc C
Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]